AMEXFinancialsAsset ManagementSnapshot 2026-10-23
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
A matching fiscal period and sufficient coverage are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Free cash flow yield improves from negative levels | A supporting condition in Marygold Companies Inc/The's published investment case. The stated target is >=0%. | Broken | free cash flow yield remains below -5% over next year | Valuation inputs unavailable A completed valuation measurement is required. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Operating income improves towards break-even by 2026-Q3 | A primary condition in Marygold Companies Inc/The's published investment case. The stated target is >=-0.14 USD_MILLIONS. | Intact | operating income remains below -$1 million next year | Operating income: $-248,000 FY2026-Q4; GAAP. Published target: >=-0.14 USD_MILLIONS. The stored target says 2026-Q3; this source reports FY2026-Q4. Fiscal/calendar alignment needs review. Source published Sep 18, 2026-248,000 USD · source valueSource reportLast status assessment Oct 24, 2026Measurement sourceconsolidated · GAAP FY2026-Q4 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q4. Source status: unverified. Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 quarters. Operating loss narrowed from $1.57 million in 2025-Q3 to $136,000 in 2026-Q3 and fiscal 2026 operating loss improved to $6.0 million from $6.8 million in 2025. Management's cost reductions and operational improvements show delivering progress toward profitability. Delivery assessment Oct 24, 2026 |
Quarterly revenue grows to at least $7.2 million by 2026-Q3 | A primary condition in Marygold Companies Inc/The's published investment case. The stated target is >=7.2 USD_MILLIONS. | Intact | quarterly revenue falls below $5.5 million next year | Revenue: $6.925M FY2026-Q4; GAAP. Published target: >=7.2 USD_MILLIONS. The stored target says 2026-Q3; this source reports FY2026-Q4. Fiscal/calendar alignment needs review. Source published Sep 18, 20266,925,000 USD · source valueSource reportLast status assessment Oct 24, 2026Measurement sourceconsolidated · GAAP FY2026-Q4 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q4. Source status: unverified. Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated as a priority in 2 quarters. Revenue grew 30.2% year-over-year to $7.2 million in 2026-Q3 and fiscal 2026 revenue increased 8% to $25.3 million from $23.4 million in 2025. USCF Investments revenue rose 55% in 2026-Q3. The trajectory shows delivering growth consistent with management's stated focus. Delivery assessment Oct 24, 2026 |
Revenue growth meets or exceeds analyst consensus of 1.8% next year | A supporting condition in Marygold Companies Inc/The's published investment case. The stated target is >=1.8% YoY. | Intact | revenue growth falls below 1.8% next year | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
Compare these dated observations with the operating requirements above
Comparable estimate history is unavailable.
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Compare required revenue and earningsMonthly analyst history is unavailable.
Recent actions · Sep 25–Oct 24 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a loss-making financial business with an improving operating trend, rather than an established durable compounder. The long-term thesis is in a watch state: management is making progress on growth and costs, but recent performance trails its industry cohort and risk remains elevated.
MGLD is valued at a substantial premium to peers, while the model has low confidence and the expectations gap is moderate. The valuation signal is tagged unjustified, but fragility is rated low because the evidence does not show the full combination of expensive valuation, weak fundamentals, and turbulence.
Near term, revenue growth and a narrower operating loss show progress toward management’s stated priorities, although the company remains loss-making and recent performance is weak. The merger agreement is approved and pending completion, so the transition adds uncertainty; a guidance cut is a stated downside risk.
Over the next several quarters, the thesis depends on continued revenue growth and further progress toward operating profitability, alongside completion of the Madison Dearborn Partners transaction. A guidance cut or falling rates would be unfavorable under the snapshot’s scenarios, while continued strong results from sector bellwethers such as BLK, BX, and KKR would support sector momentum.
For a 1 to 3 year view, MGLD has signs of operational improvement but still combines losses, elevated risk, and a peer valuation premium. The thesis hinges on execution and the pending transaction, with limited confidence in the valuation assessment. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.